Biosimilars | Association for Accessible Medicines
Generic Prescription Drugs - Your Health. Our Commitment. #Take with Confidence

Biosimilars

NAFTA 2.0: Obstacles to More Affordable Medicines

NAFTA 2.0 (USMCA) will keep drug prices out of reach for American patients.

Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.

The U.S.-Mexico-Canada Agreement (USMCA), the update to the North America Free Trade Agreement (NAFTA), contains provisions that will: 

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

WASHINGTON, DC (March 7, 2019) – “AAM is reviewing the FDA’s new draft guidance on biosimilar naming requirements and will submit comments to the docket. FDA’s current requirement of suffixes presents a significant, artificial barrier to biosimilars that is misaligned with the agency’s own Biosimilars Action Plan and the Trump administration’s commitment to lowering drug prices for America’s patients.”

Attribute to: Christine Simmon, Executive Director, Biosimilars Council

 

Christine Simmon: GRx+Biosims Combines Three Events into One

Christine Simmon, AAM Senior Vice President of Policy and Strategic Alliances and Executive Director of the Biosimilars Council, invites industry professionals to attend GRx+Biosims 2018 on Sept. 5-7 in Baltimore, MD. This year, we are combining FallTech, Leading on Biosimilars, and CMC Workshop to one can't-miss opportunity to connect with peers around the world. Attend GRx+Biosims to hear the latest from top-in-their-field speakers and government officials, share best practices and discover new learning tracks in the generic and biosimilars industry.

The Biosimilars Council Congressional Briefing: Five Takeaways

Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion with Molly Burich (Boehringer Ingelheim), Mark Fleury (American Cancer Society’s Cancer Action Network), Greg Gierer (America’s Health Insurance Plans) and Patrick Vallano (Mylan).

Subscribe to Biosimilars

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.